DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Vision - To cure lupus through partnership of scientists, clinicians, and consumers

Lupus Research Program Cover Image
»  Click on Image to View Program Booklet

Lupus Research Program Cover Image
» Click on Image to View Strategic Plan

The Lupus Research Program (LRP) was first funded in FY17 to support innovative and impactful research that addresses significant issues and gaps in lupus.

Lupus is a heterogeneous autoimmune disease that is difficult to diagnose and treat. There is currently no test available to diagnose lupus and it may take months or years for a person to be correctly diagnosed. Because lupus attacks healthy cells and tissues in many parts of the body, patients can experience a wide range of symptoms such as fatigue, joint pain, skin lesions, and headaches. Lupus can also cause inflammation in the kidneys, brain, blood vessels, lungs, and heart which can result in serious complications including organ damage. Lupus patients require a diverse team of healthcare specialists depending on their symptoms.

Treatment options for lupus are highly dependent on an individual patient's symptoms. Some of the most commonly used drugs to treat lupus include Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressants. Long-term use of these treatments can result in serious side-effects including kidney problems, stomach bleeding, liver damage, increased risk of infection, decreased fertility, and increased risk of cancer. Better treatment options are a critical need for lupus patients.

Summary of FISCAL YEAR 2017 Stakeholders Meeting


Congressional Appropriations

Congressional Appropriations

  • $5 million
    FY17
  • $5 million
    FY18

Peer Review Participants

Peer Review Participants


news_icon News & Highlights

Vision

To cure lupus through partnership of scientists, clinicians, and consumers

Mission

Fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service members, Veterans, and beneficiaries

Last updated Wednesday, September 5, 2018